Print

University of Texas MD Anderson Cancer Center Initiates Orders of IsoRay, Inc. (ISR)'s Cesium-131 for Intermediate Risk Prostate Cancer Study  
10/10/2011 10:31:34 AM

RICHLAND, Wash.--(BUSINESS WIRE)--IsoRay Inc. (AMEX: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, announced today that MD Anderson Cancer Center has initiated orders of Cesium-131 brachytherapy (internal radiation therapy) seeds as it continues its clinical research study investigating brachytherapy's ability to help control intermediate risk prostate cancer. “Intermediate risk” is a classification of early stage prostate cancer that has shown a tendency to recur following standard treatments including surgery and radiation therapy.